TargetMol

Sulindac

Product Code:
 
TAR-T0459
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0459-50mg50mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0459-100mg100mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0459-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0459-200mg200mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0459-500mg500mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Sulindac is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.
CAS:
38194-50-2
Formula:
C20H17FO3S
Molecular Weight:
356.41
Pathway:
Neuroscience; Immunology/Inflammation; Autophagy
Purity:
0.9949
SMILES:
CC1=C(CC(O)=O)c2cc(F)ccc2C1=C/c1ccc(cc1)S(C)=O
Target:
COX; Autophagy

References

1. Yamamoto Y, et al. J Biol Chem,1999, 274(38), 27307-27314. 2. Piazza GA, et al. Cancer Res,1995, 55(14), 3110-3116. 3. Boon EM, et al. Br J Cancer. 2004 Jan 12;90(1):224-9. 4. Boolbol SK, et al. Cancer Res,1996, 56(11), 2556-2560. 5. Chiu CH, et al. Cancer Res,1997, 57(19), 4267-4273. 6. Gong EY, et al. Combined treatment with vitamin C and sulindac synergistically induces p53- and ROS-dependent apoptosis in human colon cancer cells. Toxicol Lett. 2016 Sep 6;258:126-133. 7. Cha BK, et al. Celecoxib and sulindac inhibit TGF-?1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227.